An overview on cubic liquid crystalline nanoparticles-trig lipid drug delivery system


  • M. Dharani Department of Pharmaceutics, Vignan Pharmacy College,Vadlamudi, Guntur, Andhra Pradesh, India
  • K. Rama Devi Department of Pharmaceutical Analysis, Vignan Pharmacy College,Vadlamudi, Guntur, Andhra Pradesh, India.



Cubosomes, Nanoparticles, Bicontinuous, Carvenous (honeycomb), Pharmaceutical division


This type of complex structure allows them greater drug loading ability, because of increased surface area and cuboidal structures, they have simple method of preparation and have ability to encapsulate hydrophilic, hydrophobic and amphiphilic substances. Cubosomes increases the solubility of poorly soluble drugs. Cubosomal dispersions are bioadhesive and biocompatible in nature. These are versatile systems, administered by different ways such as oral, perctuneous and parental routes. Cubosomes have broad vast applications in many areas and are characterized by various parameters consequently cubosomes are in move forward of awareness by pharmaceutical development division. Cubosomes, sometimes referred to as bicontinuous cubic phase liquid crystals, are spherical, quadruple nanoparticles with an interior cubic lattice mostly composed of certain amphiphilic lipids in a particular proportion. Cubosomes often arise when a solid-like phase is dispersed into smaller particles after a surfactant or polar lipid is hydrated to form a cubic phase. With distinct qualities of practical interest, they exhibit solid like rheology. They are thermodynamically stable, self-assembling drug delivery devices. Water and lipid bicontinuous domains give cubosomes their carvenous structure. Three-dimensional bilayers are formed by tightly twisted honeycomb arrangements.


Download data is not yet available.


Almeida JD, Brand CM, Edwards DC and Heath TD (1975). Formation of Virosomes from influenza subunits and liposomes. Lancet. 2, 899-901.

Spicer PT. (2004). Cubosomes bicontinuous cubic liquid crystalline nanostructured particles. The Procter and Gamble Company, West Chester, Ohio, USA.

Luzzati V, Husson F. (1962).The structure of the liquid crystalline phases of lipid water systems.J Cell Biol; 12: 207-19.

Fernandez-moran, H., Revs. Mod. Phys., 1959, 31, 319.

Finean, J. B., J. Biophysic. And Biochem. Cytol., 1960a, 8, 13& 31.

Gallot, B., and skoulios, A. E., Compt. Rend. Acad. Sc., 1961, 252, 142.

Hartley, G. S., Progress in the Chemistry of Fats and Other Lipids, London, Pergamon Press, 1955.

Hodge, A. J., Revs. Mod. Phys., 1959, 31, 331.

Luzzati V, Tardieu A, Gulik-Krzywicki T, Rivas E, Reiss-Husson F. (1968) Structure of the cubic phases of lipid water systems. Nature; 220:485-8.

Larsson K. Two cubic phases in monoolein- water system. Nature (1983); 304: 664 - 65.

Hyde ST, Anderson S, Ericsson B, Larsson K. (1984) A cubic structure consisting of a lipid bilayer forming an infinite periodic minimal surface of the gyroid type in the glycerol monooleate water system. Z Kristallogr.; 168:213-19.

Vinod KR, Sravya K, Sandhya S, Banji D, Anbazhagan S, Prameela RA. (2013) Tailoring active compounds across biological membranes by cubosomal technology: an updated review. J Chine Pharm Sci; 22:303-11.

Urvi S, Dhiren D, Bhavin P, Patel U and Shah R. (2013). Overview of cubosomes: Nanoparticles. In. J of Ph. And Integ. Life Sci., 1(5), 36-47.

Sadhu Venkateswara Rao*, Beram Naga Sravya1and Kantamneni Padmalatha. (2018) A review on cubosome: The novel drug delivery system.GSC Biological and Pharmaceutical Sciences, 05(01), 076–081.

Tilekar KB, Khade PH, Kakade S, Kotwal S and Patil R. (2014). Cubosomes a drug delivery system. International Journal of Chemical and Biochemical Science. 4, 812-824.

Karami Z and Hamidi M. (2016). Cubosomes: Remarkable drug delivery potential. Drug Discovery Today. 21, 789–80.

Stroem P and Anderson DM. (1992). The cubic phase region in the system didodecyl dimethyl ammonium bromide-water-styrene. Langmuir. 8(2), 691-709.

Engström S, Larsson K and Lindman B. (1998). Controlled Release Bioact. Mater. 15, 105 - 106.

Anbarasan. Ba, Fatima Grace. Xa, Shanmuganathan Sa*. (2015) An overview of cubosomes - smart drug delivery system. Sri Ramachandra Journal of Medicine, Jan- June, Vol.8, Issue 1.120.

Thorat YS, Gonjari ID and Hosmani AH. (2011). Solubility enhancement techniques: a review on conventional and novel approaches. International journal of pharmaceutical sciences and research. 2(10), 2501.

Bhowmik D, Gopinath H, Kumar BP, Duraivel S and Kumar KS. (2012). Recent advances in novel topical drug delivery system. The Pharma Innovation. 1(9), 12.

Thorat YS, Gonjari ID and Hosmani AH. (2011). Solubility enhancement techniques: a review on conventional and novel approaches. International journal of pharmaceutical sciences and research. 2(10), 2501.

Bhosale RR, Osmani RA, Harkare BR andghodake PP. (2013). The Inimitable nanoparticulatedrug Carriers. Scholars Academic Journal of Pharmacy. 2(6), 481-486.

Saly S, Ehab RB and Sabry B. (2013). The design and evaluation of novel encapsulation technique for topical application of alpha lipoic acid. Journal of Advanced Pharmaceutical Research. 4(1), 13-22.

Sagnella S and Drummond C. (2012). Drug delivery a nanomedicines approach. Australian Biochemist. (43), 5-7.

Bei D, Meng J and Youan BC. (2010). Engineering nanomedicines for improved melanoma therapy progress and promises. Nanomedicines (London, England), 5(9), 1385-1399.

Angelov B, Angelova A and Garamus VM. (2012). Earliest stage of the tetrahedral nanochannelformation incubosome particles from unilamellar nanovesicles. Langmuir.28(48), 16647–16655.

Angelov B, Angelova A and Drechsler M.(2015). Identification of large channels in cationic pegylated cubosome nanoparticles by synchrotron radiation SAXS and Cryo- TEM imaging. Soft Matter. 11(18), 3686–3692.

Thadanki M, Kumari PS and Prabha KS. (2011). Overview of cubosomes: a nanoparticle. International Journal of Research in Pharmacy and Chemistry. 1(3), 535-541.

Angelova A, Angelov B and Lesieur S.(2008). Dynamic control of nanofluidic channels in protein drug delivery vehicles. Journal of Drug Delivery Science and Technology. 18(1); 41–45.

Angelova A, Angelov B and Drechsler M. (2013). Protein entrapment in pegylated lipid nanoparticles. International Journal of Pharmacy. 454(2), 625–632.

Wibroe PP, Azmi ID, Nilsson C, Yaghmur A and Moghimi SM. (2015). Citrem modulates internal nanostructure of Glyceryl monooleate dispersions and by passes complement activation: towards development of safe tunable intravenous lipid nanocarriers. Nanomedicines. 11(8), 1909–1914.

Bhowmik D, Gopinath H, Kumar BP, Duraivel S and Kumar KS. (2012). Recent advances in novel topical drug delivery system. The Pharma Innovation. 1(9), 12.[10]

Luo, Q. Et al. (2015) A Novel Glyceryl monoolein-bearing cubosomes for gambogenic acid: preparation, cytotoxicity and intracellular uptake.Int.J.Pharm.493,30–39.

Nasr,M. Etal.(2015)In Vitroandinvivoevaluation of cubosomes containing 5 ?uorouracil for liver targeting. Acta Pharma. Sin. B 5, 79–88.

Kwon,T.K. AndKim,J.C.(2014)In Vitroskinpermeationandanti-atopicef?cacyoflipidnanocarrierscontainingwatersolubleextractsofHouttuyniacordata.DrugDev.Ind.Pharm.40,1350–1357.

Tu,Y.S. Etal.(2014)Preparation, Characterisation and evaluation of curcumin with piperine-loaded cubosome nano particles.J.Microencapsul.31,551–559.

Caltagirone,C. Etal.(2014)Cancer-cell-targeted Theranostic cubosomes.Langmuir30, 6228–6236.

Meli,V. Etal.(2015)Docetaxel-loaded?uorescentliquid-crystalline nanoparticles for cancer the ranostics. Langmuir31,9566–9575.

Angelova,A. Et al.(2013)Neurotrophin Delivery using nanotechnology.DrugDiscov.Today18,1263–1271.

Moebus, K. Etal.(2012)Cubicphase-forming dry powders for controlled drug delivery on mucosal surfaces.J.Control.Release157,206–215.

Angelov,B. Etal.(2014)Multicompartment Lipid cubic nanoparticles with high protein upload:millise conddynamics of formation.ACSNano 8, 5216–5226.


79 Views | 29 Downloads

How to Cite

M, D., and R. D. K. “An Overview on Cubic Liquid Crystalline Nanoparticles-Trig Lipid Drug Delivery System ”. International Journal of Pharmaceutics and Drug Analysis, vol. 12, no. 2, June 2024, pp. 8-13, doi:10.47957/ijpda.v12i2.595.



Review Articles
Share |